Furthermore, when discontinuation of pulsatile GnRH is preferred (e.g., so that the drug delivery device can be used to treat another patient), CL support can be achieved with low amounts of exogenous hCG, with no risk of OHSS. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.